• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Cladribine: intermittent immunosuppression in MS

September 21, 2017  

New findings on gut microbiome and MS

September 13, 2017  

The return of cladribine in RRMS

August 23, 2017  

Health Canada approves Ocrevus for RRMS

August 16, 2017  

MS Sequencing: Part 6: Safety considerations when sequencing

July 26, 2017  

Delays in diagnosis, treatment: MS patient survey

July 19, 2017  

MS Sequencing: Part 5 – Strategies for optimizing response

June 29, 2017  

Progressive MS studies

May 19, 2017  

Disease-modifying therapies in MS: long-term data

May 10, 2017  

AAN 2017 DAILY REPORT

April 27, 2017  
Previous
26
27
28
29
30
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions